Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.56 |
| ▸ | CES1 | P23141 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854 | 0.92 | CES2 (0.65) | CES2CES1TSHRALOX15CA1 | |
| SCHEMBL5757987 | 0.92 | CES2 (0.65) | CES2CES1TSHRALOX15CA1 | |
| SCHEMBL1330271 | 0.92 | CES2 (0.65) | CES2CES1TSHRALOX15CA1 | |
| Hydrochloric Acid SCHEMBL5565187 | 0.90 | CES2 (0.62) | CES2CES1TSHRALOX15CA1 | |
| Bromide SCHEMBL28583978 | 0.90 | CES2 (0.62) | CES2CES1TSHRALOX15CA1 | |
| Ammonia Solution, Strong SCHEMBL28864885 | 0.90 | CES2 (0.62) | CES2CES1TSHRALOX15CA1 | |
| SCHEMBL727046 | 0.89 | ALDH1A1 (0.52) | CES2CES1TSHRCA1CA2 | |
| SCHEMBL10670934 | 0.89 | ALDH1A1 (0.52) | CES2CES1TSHRCA1CA2 | |
| SCHEMBL7349867 | 0.87 | CES2 (0.59) | CES2CES1TSHRALOX15CA1 | |
| Water SCHEMBL9342313 | 0.87 | ALDH1A1 (0.50) | CES2CES1TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2019104011-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
| EP-3033352-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015023898-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015023898-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| EP-1585515-A2 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050107434-A1 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | VTVX HOLDINGS II LLC | 2005-05-19 | — | — | US | disclosed |
| WO-2004054973-A2 | PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR | NOVO NORDISK A/S (DK) | 2004-07-01 | — | — | WO | disclosed |
| US-20020062043-A1 | Process for preparing optionally substituted biphenylcarbonyl chlorides | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-23 | — | — | US | disclosed |
| EP-1187818-A1 | PESTICIDALLY ACTIVE TETRAZINE DERIVATIVES | Syngenta Participations AG (CH) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078739-A1 | PESTICIDALLY ACTIVE TETRAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2000-12-28 | — | — | WO | disclosed |
| US-6103860-A | LOW DIELECTRIC CONSTANT, EXCELLENT TRANSPARENCY, LOW HYGROSCOPICITY AND EXCELLENT PROCESSABILITY; SUBSTRATE FOR AN OPTICAL DISK, A PICK-UP LENS, A PLASTIC SUBSTRATE FOR A LIQUID CELL AND A PRISM | MITSUI CHEMICALS, INC. (JP) | 2000-08-15 | — | — | US | disclosed |
| US-5990261-A | Organic optical component | MITSUI CHEMICALS, INC. (JP) | 1999-11-23 | — | — | US | disclosed |
| EP-0826717-A1 | An organic optical component | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1998-03-04 | — | — | EP | disclosed |
| US-4069224-A | N-(PYRIDYLALKYL)BENZAMIDES, IMPROVE PRODUCTION OF PROSTAGLANDINS IN MAMMALS | THE UPJOHN COMPANY (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | CES2 819/4885CES1 416/4885TSHR 4117/4885 |
| US-20020062043-A1 | Process for preparing optionally substituted biphenylcarbonyl chlorides | OTC, DDT, ODC1 | CES2 3000/4885CES1 2173/4885TSHR 3165/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CES2 819/4885CES1 416/4885TSHR 4117/4885 |
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | ANPEP, NPEPPS, PEPD | CES2 2176/4885CES1 2257/4885TSHR 3678/4885 |
| US-20050107434-A1 | heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders | HRH4, HRH3, HRH2 | CES2 1755/4885CES1 948/4885TSHR 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.